CBSA Highlights Breakthrough Treatments for the State”s Fast-Growing Baby Boomer and Millennial Populations

Colorado boasts one of the most rapidly expanding aging populations in the U.S., as well as one of the fastest-growing millennial populations in the country, inspiring life science companies and organizations in the state to focus on research and product development to serve patients across the care continuum. Colorado’s changing demographics have allowed Accera, a company researching Alzheimer’s disease, to open two trial sites in the state.

Additionally, 125 companies focused on digital health and the ‘quantified self’-appealing to health and wellness goals for millennials – are exploding. Another Colorado company, SomaLogic, is developing a wellness chip to enable early detection of diseases and health conditions and monitor well-being.

“Colorado’s life science sector is leading groundbreaking research to help all of us live better lives. The companies and organizations in our state are focused on fighting disease, finding cures and improving all-around quality of life.”

The magazine also highlights the state’s leadership in the prevention of infectious diseases that impact the health of all generations, with a large concentration of companies focused on outbreak prevention, along with universities and federal labs such as Colorado State University, the Rocky Mountain Centers for Disease Control and Prevention (CDC), the United States Department of Agriculture (USDA), the United States Geological Survey (USGS) and the National Wildlife Research Center (NWRC).

“The state of Colorado deserves credit for the continued expansion of our life science industry. Since 2006, Colorado has awarded more than 333 life-science-related grants and provided more than $37 million in matching grant funding to bioscience ventures. That early investment has generated more than $465.4 million in follow-on grants and investments for these companies, allowing them to launch clinical studies, fund the development of medical devices and bring new drugs to market.”